SCHEDULE 13G: Regal Funds Management Discloses Significant Stake in Radiopharm Theranostics

Regal Funds Management Pty Limited and Regal Partners Limited have disclosed a beneficial ownership of 7.96% in Radiopharm Theranostics Limited, totaling 175,080,633 shares, as of December 31, 2024.

Summary

• Regal Funds Management Pty Limited and Regal Partners Limited have filed a Schedule 13G with the SEC, reporting their beneficial ownership in Radiopharm Theranostics Limited.
• As of December 31, 2024, the aggregate beneficial ownership amounts to 175,080,633 shares, which represents 7.96% of the class of securities.
• The reported ownership includes 147,807,933 Ordinary Shares and 90,909 American Depositary Shares (ADS), with each ADS representing three hundred Ordinary Shares.
• Regal Funds Management Pty Limited is classified as an investment adviser.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The disclosure of a significant institutional investor holding a substantial stake is generally viewed as a positive signal of investor confidence, although the filing itself is a routine regulatory requirement and does not contain operational news.

Positives

• Disclosure of a significant institutional investor, Regal Funds Management, holding a substantial stake (7.96%) in Radiopharm Theranostics Limited, which can be viewed as a vote of confidence.
• The filing indicates the shares are held in the ordinary course of business, suggesting a passive investment rather than an activist intent to influence control.

Future Outlook

NA

Industry Context

This filing is a standard regulatory disclosure required when an entity acquires beneficial ownership exceeding 5% of a company's shares. It provides transparency regarding significant institutional holdings in the biotechnology and radiopharmaceutical sector, indicating investor interest in companies like Radiopharm Theranostics.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially influencing market perception and liquidity.

Key Dates

Keywords

SEC filing, Schedule 13G, beneficial ownership, Radiopharm Theranostics Limited, Regal Funds Management Pty Limited, Regal Partners Limited, Ordinary Shares, American Depositary Shares, investment adviser, shareholding disclosure